The economic evaluations on neoadjuvant HER2-targeted therapy in breast cancer treatments are limited and are primarily from high-income countries25–27 along with few upper-middle income countries (upper-MICs)28,29. The gene discussed is ERBB2; the disease is breast carcinoma.